| Antibody drug conjugates (ADCs) are class of targeted therapies that combine precise targeting capabilities of monoclonal antibodies with the potent effects of cytotoxic payloads. Known for their ability to selectively identify and destroy cancer cells, ADCs represent a groundbreaking advancement in oncology. |
|
|
| Figure 1. The structure and functions of an ADC drug[1]. |
| Main Components: Antibody , linker , and cytotoxic payload. |
| Targeting and Action: Upon binding to the target antigen, the ADCs are internalized into the cancer cell via receptor-mediated endocytosis. Inside the cell, the ADCs are transported to endosomes, which subsequently fuse with lysosomes. The cytotoxic payloads are released through chemical or enzymatic process, effectively killing the cancer cell. |
|
|
| Figure 2. Direct mechanism of action and bystander effects of ADCs[2]. |
| ‘X’DC |
| The success of ADC has spurred innovation in conjugated drug (XDC) technologies. This approach uses targeting ligands to selectively deliver therapeutic agents to the site of disease, improving efficacy and minimizing side effects. The field has seen rapid growth, evolving into a diverse array of conjugated therapies that redefine precision medicine. |
| MedChemExpress Provide More Than ADCs |
| At MCE, we go beyond ADCs to offer a diverse portfolio of conjugated drug technologies (XDCs), including: |
|
|
| These cutting-edge technologies are widely used in anti-tumor research, disease diagnosis, and therapeutic applications. |
| References: |
[1] Fu Z, et al. Signal Transduct Target Ther. 2022;7(1):93.
[2] JMark C, et al. Int J Mol Sci. 2023 Sep 6;24(18):13726. |
|
 |
